Work

Biomarker Associations With Survival for Refractory NSCLC Patients Receiving Erlotinib +/- Sunitinib in a Randomized Phase 2 Trial

Year: 2010

Type: article

Source: University of Groningen research database (University of Groningen / Centre for Information Technology)

Authors: Groen, H. J. M., Harmon, C. S., Williams, J. A., Gao, F., Socinski, M. A., Grossi, F., Gridelli, C., Tye, L., Chao, R. C., Blumenschein, G.

Institutions: Pfizer (United States), University of North Carolina at Chapel Hill, Azienda Ospedaliera S.Giuseppe Moscati, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2528689852

FWCI:

Cites:

Cited by: 1

Related to: 10